115
Views
2
CrossRef citations to date
0
Altmetric
Research Article

Dysregulation of miR-374a is involved in the progression of diabetic retinopathy and regulates the proliferation and migration of retinal microvascular endothelial cells

, , &
Pages 287-292 | Received 05 Feb 2021, Accepted 26 Mar 2021, Published online: 03 May 2021
 

ABSTRACT

Clinical relevance

microRNAs (miRNAs) have been reported to be involved in the progression of various diseases.

Background

This study evaluated the expression and clinical value of miR-374a in diabetic retinopathy (DR) patients and analysed the effects of miR-374a on the progression of DR.

Methods

Subjects were divided into four groups: healthy control, type 2 diabetes mellitus without DR (NDR), proliferation DR (PDR) and non-proliferation DR (NPDR). Real-time polymerase chain reaction (qRT-PCR) was detected in the serum miR-374a levels of the subjects. The receiver operating characteristic (ROC) curve was used to evaluate the diagnostic value of miR-374a in DR patients. Pearson correlation was used to analyse the correlation between miRNA and clinical indicators of patients. High glucose (HG) in treatment of human retinal microvascular endothelial cells (HRMECs). The effects of miR-374a on cell proliferation and migration induced by HG were detected.

Results

Serum miR-374a was progressively accelerated in patients with NDR, NPDR and PDR than in healthy controls. Moreover, miR-374a can significantly distinguish between NDR and DR patients. Among DR patients, miR-374a can differentiate PDR patients from NPDR patients. Serum miR-374a was positively correlated with diabetes duration, fasting plasma glucose (FPG), glycosylated haemoglobin (HbA1c), and homoeostasis model assessment of insulin resistance (HOMA-IR) in DR patients. HG-induced proliferation and migration of HRMECs was inhibited by reduction of miR-374a.

Conclusion

Dysregulation of miR-374a is involved in the progression of DR and serves a regulatory role in retinal, which can be used as a promising diagnostic biomarker for DR.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.